Pharmacological therapy in adult congenital heart disease: growing need, yet limited evidence

Area of Science:

• Cardiology
• Adult Congenital Heart Disease
• Pharmacology

Background:

• Congenital heart disease (CHD) is the most common birth defect.
• Advances in pediatric care have led to a growing adult CHD population requiring lifelong management.
• Adults with CHD often have residual conditions necessitating ongoing medical and interventional care.

Purpose of the Study:

• To review the rationale, evidence, and knowledge gaps in pharmacotherapy for adult congenital heart disease.
• To discuss drug therapy options for common late complications in adults with CHD.
• To highlight the need for evidence-based guidelines in this specialized field.

Main Methods:

• Review of existing literature on drug therapy in adult CHD.
• Analysis of pharmacotherapy for specific conditions including heart failure, arrhythmias, and pulmonary hypertension.
• Discussion of knowledge gaps and future research directions.

Main Results:

• Drug therapy for adult CHD is largely empiric due to scarce clinical data.
• Pharmacological interventions are individualized to manage symptoms and hemodynamic compromise.
• Formalized guidelines for drug therapy in adult CHD are currently lacking.

Conclusions:

• Adults with CHD require individualized pharmacotherapy for late complications, often based on limited evidence.
• Further research is crucial to develop evidence-based guidelines for managing adult CHD.
• Addressing knowledge gaps in drug therapy is essential for improving long-term outcomes in this population.